Agilex Biolabs CEO Jason Valentine said, "TetraQ complements the Agilex Biolabs work in Australia and APAC with its expert staff and years of experience in regulated bioanalytical services. The TetraQ purchase is part of our regional expansion plans. Agilex Biolabs is already the largest and most technologically advanced biolab in Australia, and the TetraQ addition to the business will further expand support for biotech clients running trials in Australia."
"We are also looking forward to introducing our clients to the well-established TetraQ toxicology capabilities for their discovery and pre-clinical work in Australia, which can also attract the 43.5% tax rebate. The clinical trials bioanalytics sector is one of the fastest-growing services globally with Australia and APAC a preferred location for conducting trials - especially since the COVID-19 pandemic."
Agilex Biolabs specializes in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarker and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay and flow cytometry. Agilex also offers pharmacodynamics services that include immunobiology services using the latest technology to support immunology, cell biology and mode of action assays.
Agilex Biolabs has 75 dedicated lab staff, and supports clinical research for biotech clients in the U.S., Europe and APAC.